DK1135153T3 - Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser - Google Patents
Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelserInfo
- Publication number
- DK1135153T3 DK1135153T3 DK99960524T DK99960524T DK1135153T3 DK 1135153 T3 DK1135153 T3 DK 1135153T3 DK 99960524 T DK99960524 T DK 99960524T DK 99960524 T DK99960524 T DK 99960524T DK 1135153 T3 DK1135153 T3 DK 1135153T3
- Authority
- DK
- Denmark
- Prior art keywords
- agonists
- treatment
- eph receptor
- receptor antagonists
- vascular disorders
- Prior art date
Links
- 102000050554 Eph Family Receptors Human genes 0.000 title abstract 2
- 108091008815 Eph receptors Proteins 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 208000019553 vascular disease Diseases 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10927598P | 1998-11-20 | 1998-11-20 | |
PCT/US1999/027534 WO2000030673A1 (en) | 1998-11-20 | 1999-11-18 | Uses for eph receptor antagonists and agonists to treat vascular disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1135153T3 true DK1135153T3 (da) | 2005-08-15 |
Family
ID=22326793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99960524T DK1135153T3 (da) | 1998-11-20 | 1999-11-18 | Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser |
Country Status (12)
Country | Link |
---|---|
US (3) | US20040136983A1 (da) |
EP (1) | EP1135153B1 (da) |
JP (2) | JP2002530350A (da) |
AT (1) | ATE293989T1 (da) |
AU (1) | AU766077C (da) |
CA (1) | CA2351311A1 (da) |
DE (1) | DE69925024T2 (da) |
DK (1) | DK1135153T3 (da) |
ES (1) | ES2242437T3 (da) |
IL (1) | IL142921A0 (da) |
PT (1) | PT1135153E (da) |
WO (1) | WO2000030673A1 (da) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
US6887674B1 (en) | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
GB9905124D0 (en) * | 1999-03-05 | 1999-04-28 | Smithkline Beecham Biolog | Novel compounds |
CA2380888A1 (en) * | 1999-08-17 | 2001-02-22 | Purdue Research Foundation | Treatment of metastatic disease |
US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
EP1695702A3 (en) * | 1999-08-17 | 2012-01-11 | Purdue Research Foundation | Treatment of metastatic disease |
EP1246637A2 (en) * | 2000-01-06 | 2002-10-09 | The Hospital for Sick Children | Methods of modulation of the immune system |
WO2001083525A2 (en) * | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides, comprising an fc domain, as therapeutic agents |
US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
WO2002026827A1 (en) * | 2000-09-29 | 2002-04-04 | Novartis Ag | Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules |
AU2002232405A1 (en) | 2000-11-20 | 2002-05-27 | California Institute Of Technology | Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
CA2431313A1 (en) * | 2000-12-08 | 2002-08-01 | Eos Biotechnology, Inc. | Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
WO2003004529A2 (en) * | 2001-07-02 | 2003-01-16 | Licentia Ltd. | Ephrin-tie receptor materials and methods |
CA2452578A1 (en) * | 2001-07-03 | 2003-01-16 | The Hospital For Sick Children | Ephrin and eph receptor mediated immune modulation |
US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
ES2373715T3 (es) * | 2002-05-10 | 2012-02-08 | Medimmune, Llc | Anticuerpos monoclonales frente a epha2 y procedimientos de uso de los mismos. |
ATE530577T1 (de) * | 2002-05-10 | 2011-11-15 | Purdue Research Foundation | Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren |
GB0215389D0 (en) * | 2002-07-03 | 2002-08-14 | King S College London | Receptor |
AU2002951409A0 (en) * | 2002-09-16 | 2002-09-26 | North Western Adelaide Health Services | Methods for regulating cancer |
AU2003260169B9 (en) * | 2002-09-16 | 2011-06-09 | The Queen Elizabeth Hospital Research Foundation Inc. | Methods for regulating cancer |
WO2004028551A1 (en) | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
AU2003900541A0 (en) * | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
WO2004080425A2 (en) | 2003-03-12 | 2004-09-23 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
US20050049176A1 (en) * | 2003-04-11 | 2005-03-03 | Kiener Peter A. | EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
US20050147593A1 (en) * | 2003-05-22 | 2005-07-07 | Medimmune, Inc. | EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders |
US20050153923A1 (en) * | 2003-12-04 | 2005-07-14 | Kinch Michael S. | Targeted drug delivery using EphA2 or EphA4 binding moieties |
US7264841B2 (en) | 2004-01-21 | 2007-09-04 | Linda Kalustian Lester | Savory gluten-free foods |
EP2275445A3 (en) * | 2004-03-12 | 2012-02-29 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
KR20070034465A (ko) * | 2004-03-12 | 2007-03-28 | 바스진 테라퓨틱스, 인크. | 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물 |
JP2008510008A (ja) | 2004-08-16 | 2008-04-03 | メディミューン,インコーポレーテッド | 抗体依存性細胞性細胞傷害活性が増強されたインテグリンアンタゴニスト |
US20080254023A1 (en) * | 2004-09-08 | 2008-10-16 | The University Of Queensland | Treating Gliosis, Glial Scarring, Inflammation or Inhibition of Axonal Growth in the Nervous System by Modulating Eph Receptor |
JP2008514925A (ja) * | 2004-09-23 | 2008-05-08 | バスジーン セラピューティクス, インコーポレイテッド | 腫瘍を検出し且つ治療するための組成物及び方法 |
EP1799713B1 (en) * | 2004-09-23 | 2014-11-05 | VasGene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
WO2006081418A2 (en) | 2005-01-27 | 2006-08-03 | The Burnham Institute | Ephb receptor-binding peptides |
US20070218061A1 (en) * | 2005-09-23 | 2007-09-20 | Vasgene Therapeutics, Inc. | Use of ephrinb2 directed agents for the treatment or prevention of viral infections |
AU2006300222A1 (en) * | 2005-10-05 | 2007-04-19 | Aqumen Biopharmaceuticals K.K. | Method of inhibiting angiogenesis by using ephrin B2 |
JP5368110B2 (ja) | 2006-01-20 | 2013-12-18 | ジェネンテック, インコーポレイテッド | 抗エフリンb2抗体とその使用方法 |
JP5406027B2 (ja) | 2006-08-04 | 2014-02-05 | ノバルティス アーゲー | EphB3特異的抗体およびその使用 |
US20100093626A1 (en) * | 2006-12-15 | 2010-04-15 | Bingcheng Wang | Peptide and small molecule agonists of epha and their uses in disease |
WO2009023185A1 (en) | 2007-08-13 | 2009-02-19 | Vasgene Therapeutics, Inc. | Cancer treatment using humanized antibodies that bind to ephb4 |
DK2498796T3 (da) | 2009-11-09 | 2018-03-05 | Aal Scient Inc | Behandling af hjertesygdom |
US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
CN113398267B (zh) * | 2020-03-17 | 2023-05-05 | 中国医学科学院药物研究所 | EphB4作为靶标在筛选增加胰岛素敏感性药物或模型中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5001225A (en) * | 1986-12-08 | 1991-03-19 | Georgetown University | Monoclonal antibodies to a pan-malarial antigen |
US6017954A (en) * | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
US5635177A (en) * | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
US5824303A (en) * | 1992-11-13 | 1998-10-20 | Amgen Inc. | Eck receptor ligands |
US5512591A (en) * | 1993-02-18 | 1996-04-30 | President And Fellows Of Harvard College | Treatments for diseases characterized by neovascularization |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5624899A (en) * | 1994-07-20 | 1997-04-29 | Genentech Inc. | Method for using Htk ligand |
US5795734A (en) * | 1994-09-19 | 1998-08-18 | President And Fellows Of Harvard College | EPH receptor ligands, and uses related thereto |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
JP2000513932A (ja) * | 1996-06-19 | 2000-10-24 | リジェネロン ファーマシューティカルズ,インコーポレイテッド | Tie―2レセプターリガンド(tieリガンド―3;tieリガンド―4)およびそれらの使用 |
WO1999008696A1 (en) * | 1997-08-19 | 1999-02-25 | Vanderbilt University | METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS |
JP2001518318A (ja) * | 1997-10-02 | 2001-10-16 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Lerk−2媒介細胞接着の調節 |
US6864227B1 (en) * | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
-
1999
- 1999-11-18 AT AT99960524T patent/ATE293989T1/de not_active IP Right Cessation
- 1999-11-18 ES ES99960524T patent/ES2242437T3/es not_active Expired - Lifetime
- 1999-11-18 EP EP99960524A patent/EP1135153B1/en not_active Revoked
- 1999-11-18 WO PCT/US1999/027534 patent/WO2000030673A1/en active IP Right Grant
- 1999-11-18 DK DK99960524T patent/DK1135153T3/da active
- 1999-11-18 AU AU17397/00A patent/AU766077C/en not_active Ceased
- 1999-11-18 JP JP2000583556A patent/JP2002530350A/ja active Pending
- 1999-11-18 DE DE69925024T patent/DE69925024T2/de not_active Revoked
- 1999-11-18 PT PT99960524T patent/PT1135153E/pt unknown
- 1999-11-18 CA CA002351311A patent/CA2351311A1/en not_active Abandoned
- 1999-11-18 IL IL14292199A patent/IL142921A0/xx unknown
-
2004
- 2004-02-02 US US10/770,543 patent/US20040136983A1/en not_active Abandoned
- 2004-06-16 US US10/870,027 patent/US20040234520A1/en not_active Abandoned
-
2005
- 2005-09-14 JP JP2005267683A patent/JP2006016404A/ja not_active Withdrawn
-
2006
- 2006-10-06 US US11/544,243 patent/US20070031434A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2242437T3 (es) | 2005-11-01 |
AU766077C (en) | 2004-10-07 |
AU1739700A (en) | 2000-06-13 |
DE69925024D1 (de) | 2005-06-02 |
EP1135153A1 (en) | 2001-09-26 |
EP1135153B1 (en) | 2005-04-27 |
CA2351311A1 (en) | 2000-06-02 |
WO2000030673A1 (en) | 2000-06-02 |
US20070031434A1 (en) | 2007-02-08 |
JP2006016404A (ja) | 2006-01-19 |
DE69925024T2 (de) | 2006-03-02 |
PT1135153E (pt) | 2005-09-30 |
US20040234520A1 (en) | 2004-11-25 |
US20040136983A1 (en) | 2004-07-15 |
ATE293989T1 (de) | 2005-05-15 |
AU766077B2 (en) | 2003-10-09 |
JP2002530350A (ja) | 2002-09-17 |
IL142921A0 (en) | 2002-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1135153T3 (da) | Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser | |
MXPA02005602A (es) | Compuestos de urea que tienen actividad antagonista para el receptor muscarinico. | |
WO2004058717A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
DE69821132D1 (de) | 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes | |
ATE324444T1 (de) | Tek-antagonisten | |
TR200102021T2 (tr) | TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları | |
FI960727A0 (fi) | Neurokiniiniantagonisteina käyttökelpoiset heterosyklit | |
BR9911575A (pt) | Heterocìclicos de alquilsulfóxido 4-benzil piperidina e seu uso como antagonistas receptores de nmda seletivas do subtipo | |
IS6750A (is) | Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka | |
ES2196361T3 (es) | Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr. | |
ATE303804T1 (de) | Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten | |
AP2001002129A0 (en) | 5HT1 receptor agonists and metoclopramide for the treatment of migrane. | |
DK1129091T3 (da) | Antagonister for CRF-receptorer og fremgangsmåder med relation dertil | |
DK1176963T3 (da) | Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser | |
EA200400734A1 (ru) | Способ и композиция для потенциирования действия опиатного анальгетика | |
YU13301A (sh) | Muskarinski agonisti i antagonisti | |
BR0012175A (pt) | Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca | |
DK0946157T3 (da) | Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte | |
SE9903995D0 (sv) | New combination | |
DK1342410T3 (da) | Anvendelse af en galaninagonist til fremstilling af et medikament til forbedring af hukommelse og andre kognitive funktioner | |
DE60015187D1 (de) | Urotensin-ii rezeptorantagonisten | |
TR200100240T2 (tr) | Anksiyete bozukluklarının tedavisi | |
SE0001373D0 (sv) | NPY Y1 receptor agonists and antagonists | |
EP1508337A3 (en) | Uses for eph receptor antagonists and agonists to treat vascular disorders | |
ATE230265T1 (de) | Zusammensetzung von alpha-adrenergen antagonisten mit stickstoffoxiddonoren zur behandlung von sexualfunktionsstörungen bei frauen |